Serina Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 12,500,000 Shares Of Common Stock By Roth Principal Investments
-SEC Filing
Read original at benzingaStocks · News reference
8-K filing — Serina Therapeutics, Inc. (SER)
Filed: 2026-08-27 AccNo: 0001708599-26-000051 Size: 254 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 26, 2026, 10:24 PM
- Checked
- Aug 26, 2026, 10:24 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Serina Therapeutics Q2 EPS $(0.55) Misses $(0.47) Estimate, Sales $130.000K, Same YoY
Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.47) by 19.57 percent. This is a 16.67 percent increase over losses of $(0.66) per share
Read original at benzingaSerina Therapeutics Completes Enrollment And Dosing In Cohort 1 Of Ongoing Phase 1b Registrational Clinical Trial Evaluating SER-252 In Patients With Advanced Parkinson’s Disease
- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 -- Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in
Read original at benzinga